Published in Clin Infect Dis on March 15, 2007
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother (2010) 1.49
Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clin Infect Dis (2016) 1.46
Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol (2008) 1.39
Unresolved antiretroviral treatment management issues in HIV-infected children. J Acquir Immune Defic Syndr (2012) 1.17
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother (2008) 1.10
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother (2012) 1.04
Interactions between malaria and human immunodeficiency virus anno 2014. Clin Microbiol Infect (2014) 0.99
Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. Malar J (2014) 0.96
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. PLoS One (2012) 0.95
In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet (2013) 0.91
Malaria in children. Mediterr J Hematol Infect Dis (2012) 0.86
The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa. Future Virol (2012) 0.84
Malaria and hiv in adults: when the parasite runs into the virus. Mediterr J Hematol Infect Dis (2012) 0.81
Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settings. J Comp Eff Res (2012) 0.81
Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa. Curr Drug Metab (2011) 0.79
Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. J Antimicrob Chemother (2014) 0.78
Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N-desethylamodiaquine. Br J Clin Pharmacol (2016) 0.75
Potential drug-drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria. HIV AIDS (Auckl) (2014) 0.75
Impact of comorbidity on adverse drug reaction profile in a cohort of patients treated with Artemisinin combination therapies for uncomplicated malaria in Nigeria. Pharmacol Res Perspect (2017) 0.75
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLoS One (2017) 0.75
The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation. PLoS One (2016) 0.75
Hematological and biochemical effects of sub-chronic artesunate exposure in rats. Toxicol Rep (2015) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda. J Infect Dis (2008) 4.60
Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health (2006) 4.44
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
Treatment of malaria restricted to laboratory-confirmed cases: a prospective cohort study in Ugandan children. Malar J (2007) 4.05
Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov (2004) 3.90
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet (2006) 3.90
Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet (2002) 3.78
Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg (2003) 3.71
Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One (2013) 3.66
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA (2007) 3.62
Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Med (2013) 3.23
Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a randomised controlled trial. Lancet (2009) 3.21
Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet (2004) 3.12
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet (2007) 2.99
Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A (2011) 2.94
Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ (2009) 2.84
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One (2008) 2.78
Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother (2006) 2.74
Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials (2006) 2.72
Short report: proximity to mosquito breeding sites as a risk factor for clinical malaria episodes in an urban cohort of Ugandan children. Am J Trop Med Hyg (2003) 2.68
Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. AIDS Patient Care STDS (2003) 2.67
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials (2007) 2.63
Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett (2003) 2.54
Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis (2005) 2.51
Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop (2011) 2.46
Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis (2007) 2.44
Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg (2006) 2.43
Improved malaria case management after integrated team-based training of health care workers in Uganda. Am J Trop Med Hyg (2008) 2.42
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis (2009) 2.42
Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc Natl Acad Sci U S A (2004) 2.33
Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med (2005) 2.33
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Comparison of HRP2- and pLDH-based rapid diagnostic tests for malaria with longitudinal follow-up in Kampala, Uganda. Am J Trop Med Hyg (2007) 2.30
Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J Infect Dis (2008) 2.28
Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis (2010) 2.24
Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One (2011) 2.24
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother (2007) 2.12
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis (2008) 2.08
Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One (2009) 2.05
High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis (2008) 2.05
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (2005) 2.00
Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis (2011) 1.98
Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis (2012) 1.97
Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg (2003) 1.96
Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother (2006) 1.95
Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis (2011) 1.94
Improved malaria case management through the implementation of a health facility-based sentinel site surveillance system in Uganda. PLoS One (2011) 1.94
Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis (2006) 1.93
A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS One (2008) 1.92
Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop Med Int Health (2008) 1.85
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother (2010) 1.83
Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr (2009) 1.83
Surveillance for malaria elimination in Swaziland: a national cross-sectional study using pooled PCR and serology. PLoS One (2012) 1.81